Effect of erythropoietin-stimulating agent on uremic inflammation
© Tanaka et al.; licensee BioMed Central Ltd. 2012
Received: 14 December 2011
Accepted: 14 May 2012
Published: 14 May 2012
The goal of the present study was to explore the effect of medications that are commonly prescribed for CKD patients on uremic state.
This was a cross-sectional study. From January 2006 to October 2009, 1,623 patients with end-stage kidney disease (ESKD) commenced hemodialysis (HD) at the 9 participating hospitals. The criteria for exclusion from the database were 1) serum C-reactive protein (CRP) > 3 mg/dL, 2) WBC count > 9,000/mm3 or <4,000/mm3, and 3) patients with cancer, immune complex disease, or vasculitis. A total of 900 patients were entered into the final database. We explored the association of serum CRP just before the first HD session with clinical characteristics, laboratory data, and medications for CKD in the predialysis period.
On univariate analysis, age, CTR, eGFR, and WBC were significantly correlated with CRP. Systolic and diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Use of erythropoietin-stimulating agents (ESA) using (r = −0.111, p = 0.0015), renin-angiotensin-aldosterone system inhibitors (r = −0.083, p = 0.0154), and calcium channel blockers (r = −0.1, p = 0.0039) was also negatively correlated with CRP. However, only use of ESA showed a significant negative correlation with CRP that was independent of other clinical factors and CKD medications on multiple regression analysis.
ESA may strongly reduce uremic inflammation in addition to improving anemia. To confirm this potential effect, a large-scale longitudinal study would be required.
KeywordsInflammation CRP Erythropoietin stimulating agent ACE-I/ARB Initiation of dialysis
Although the mechanism of cardio-renal syndrome has been elucidated in considerable detail during the past decade , atherosclerotic cardiovascular disease is still the leading cause of death in patients with chronic kidney disease (CKD) [2, 3]. Along with the accumulation of traditional atherogenic risk factors, factors specific to uremia, such as anemia, dyslipidemia, abnormal calcium (Ca)/phosphate (P) metabolism, insulin resistance, oxidative stress, malnutrition, and inflammation, play an important role in such rapid progression of atherosclerosis [4, 5]. In particular, chronic inflammation and oxidative stress are thought to be possible treatment targets in the clinical setting .
According to the international guidelines , strict blood pressure control by using an renin-angiotensin-aldosterone (RAS) system blocker combined with other antihypertensive agents, regulation of calcium/phosphate metabolism with vitamin D or calcium therapy, and maintaining an optimum hemoglobin concentration with erythropoietin-stimulating agents (ESAs) and iron are three main essential treatments for renoprotection and a better prognosis in CKD patients. Recently, it has been suggested that medications for CKD could have possible pleiotropic effects, especially an anti-inflammatory effect. For instance, RAS blockers , vitamin D , and ESA  have already been shown to have anti-inflammatory activity in clinical and basic studies. However, there is still limited evidence about the effect of common treatments for CKD on inflammation in the clinical setting. The goal of the present study was to explore the effect of medications that are commonly used by CKD patients on the serum level of C-reactive protein (CRP) at the initiation of renal replacement therapy (RRT).
Patients and methods
Study design & patients
The body mass index (BMI) at optimal weight was calculated as the weight in kilograms divided by the square of the height in meters. The cardiothoracic ratio (CTR) was determined at the optimal body weight after HD.
Data are expressed as the mean ± SD. To assess the association of various factors with inflammation, Pearson’s univariate regression analysis was employed to compare clinical factors with CRP. Dummy variables were used for gender (0 for female, 1 for male), primary renal disease (0 for non-diabetic nephropathy, 1 for diabetic nephropathy), smoking history (0 for negative, 1 for positive), and each CKD treatment (0 for not used, 1 for used). The monthly ESA dose was evaluated as a numerical factor. Multivariate regression analysis was also performed to identify independent determinants of the serum CRP concentration. In all analyses, a probability (P) value < 0.05 was considered statistically significant. All statistical analyses were performed using StatView for Windows version 5.0 (SAS Institute, Cary, NC).
Demographic characteristics of 900 new dialysis patient who enrolled into the study
Clinical characteristics of the study population
65.5 ± 13.7
Male sex (%)
23.0 ± 4.0
153 ± 26
78 ± 15
54 ± 7
Polycystic kidney disease
Duration of nephrologist care, months
33 ± 43
6160 ± 1270
8.5 ± 1.5
Plt x 104, mm3
19.4 ± 7.1
3.3 ± 0.6
98 ± 41
47 ± 17
9.5 ± 3.5
89 ± 27
Uric acid, mg/dL
8.6 ± 2.2
eGFR, mL/min/1.73 m2
5.4 ± 2.9
7.8 ± 1.0
6.0 ± 1.6
304 ± 214
0.48 ± 0.68
18.9 ± 5.0
ESA dose, u/month
17813 ± 6580
ARB or ACE-I (%)
ARB and ACE-I (%)
other anti-HT drugs (%)
Vitamin D (%)
Calcium agents (%)
Iron agents (%)
During the predialysis phase of CKD, about 70% of our subjects used ESA and the mean monthly dose was 17813 ± 6580 units. About 60% and 20% were using RAS inhibitor and vitamin D, respectively. Other medications are shown in Table 1.
Univariate analysis of factors associated with CRP
Univariate linear regression analysis of factors correlated with the serum CRP concentration
Sex (F: 1, M: 2)
Diabetic nephropathy (no: 1, yes: 2)
Duration of nephrologist care
ARB or ACE-I
ARB and ACE-I
Univariate analysis of CKD treatments associated with CRP
Linear regression analysis of the association between CKD treatments and the serum CRP concentration #
−0.274 - -0.065
−0.014 - -0.003
−0.196 - -0.012
−0.221 - 0.012
ARB or ACE-I
−0.212 - -0.022
ARB and ACE-I
−0.267 - 0.005
−0.241 - -0.046
−0.188 - 0.001
−0.190 - 0.046
−0.220 - 0.007
−0.334 - 0.003
Multivariate analysis of CKD treatments associated with CRP
Multiple linear regression analysis of factors associated with the serum CRP concentration
ARB or ACE-I
It is well established that chronic inflammation plays a crucial role in the progression of uremic atherosclerotic cardiovascular disease in CKD patients [15–17]. There is increasing evidence of a relationship between the serum level of CRP, a marker of chronic inflammation, and cardiovascular disease in these patients [15, 18]. The present study demonstrated that at the initiation of RRT 1) 35% of ESKD patients had abnormally high CRP levels; 2) CRP was positively correlated with age, CTR, and eGFR, and negatively correlated with blood pressure, albumin, HDL-C, HDL-C, and Hb; 3) use of ESA showed an independent inverse correlation with CRP. These findings imply that use of ESA in the predialysis phase of CKD has an anti-inflammatory effect and would be beneficial for prevention of progression of atheroscletic complications.
Chronic inflammation is thought to be one of the central reasons for the high incidence and prevalence of atherosclerotic cardiovascular disease in CKD patients . CRP is a well known marker of inflammation in the general population . In CKD patients, it has been reported that CRP is closely associated with the severity of atherosclerosis and cardiovascular events [17, 18]. Indeed, several reports have suggested that CRP could be associated with atherosclerosis through various mechanism such as 1) release of reactive oxygen species, 2) increased expression of adhesion molecules, 3) induction of foam cell formation, and 4) destabilization of plaque . If CRP is involved in the pathophysiology of cardiovascular disease, it could be expected that reducing the CRP level would prevent the development of cardiovascular complications. In the present study, use of ESA, RAS-I, and CCB during the predialysis period showed a significant inverse correlation with serum CRP. Although we do not have any information about the duration of such treatments in the predialysis phase of CKD, the effect of each medication on CRP remained significant after adjustment for the duration of care by a nephrologist. This may imply that ESA, RAS-I, and CCB have an anti-inflammatory effect in the predialysis phase of CKD which is independent of the duration of treatment.
Treatment with RAS-I is well known to reduce chronic inflammation in CKD patients. In the current study, 60% of the subjects were on treatment with RAS-I in the predialysis period and most of them received ARB. At least 6 ARB are recognized to have an anti-inflammatory effect and have been shown to reduce CRP in clinical studies. Dohi et al . reported that candesartan treatment for 12 weeks decreased the serum level of CRP by 14% in patients with essential hypertension. In addition, valsartan therapy for 8 months reduced CRP by 39% in hypertensive patients with left ventricular hypertrophy  or with other cardiovascular risk factors , while 3 months of irbesartan therapy for patients with coronary artery disease significantly reduced the plasma CRP level . A large-scale prospective, double-blind, placebo-controlled, multicenter study performed in patients with essential hypertension and microinflammation also showed that olmesartan therapy significantly reduced the serum level of CRP . Moreover, reduction of serum CRP was observed after losartan was administered for 28 days to patients who had interstitial inflammation and fibrosis associated with chronic cyclosporine-induced nephropathy . Finally, treatment with telmisartan for 3 months reduced the serum level of CRP by 38% in diabetic patients . It is interesting that irrespective of the underlying disease and the duration of treatment, an anti-inflammatory effect of ARB therapy was confirmed. These reports support our finding that the beneficial anti-inflammatory effect of ARB was still detectable after adjusting for the duration of care by a nephrologist. There have also been several studies into the effects of ACE-I on CRP in various diseases [26–28].
Compared with ARB, less is known about the clinical effect of CCB on CRP, but a few studies have clearly shown a suppressive effect of CCB on inflammation. After 3 months of CCB treatment, reduction of the serum CRP level was observed in patients with vasospastic angina . Also, the combination of a RAS-I with the CCB azelnidipine decreased serum CRP more than combined therapy with other CCB . This implies that the effect on CRP may depend on the type of CCB. Unfortunately, no information concerning the type of CCB was included in our database, so we could not investigate this issue.
Intriguingly, use of ESA was strongly associated with a lower CRP level in the current study. This association remained even after adjusting for RAS-I and CCB, as well as other variables. Several other reports support our finding of an inverse association between use of ESA and the serum level of CRP. To our knowledge, Agnello et al. first identified a possible anti-inflammatory effect of ESA in an experimental rat model of autoimmune encephalomyelitis . They showed that ESA decreased the peak clinical severity of experimental autoimmune encephalomyelitis in a dose-dependent manner, with a simultaneous marked decrease of TNF and the pro-inflammatory cytokine IL-6 in the spinal cord. In the clinical field, Kourea et al . demonstrated in their single-blind, placebo-controlled trial that patients with anemic congestive heart failure who received combined treatment using the erythropoietin analogue darbepoietin-α and oral iron had a greater increase of Hb than those treated with placebo plus oral iron, and also showed concomitant improvement of cardiac contractility. As a possible mechanism of this cardioprotective effect, they confirmed an approximately 40% decrease of IL-6 (a pro-inflammatory cytokine) by treatment with darbepoietin-α, compared with an increase of about 20% after placebo treatment. This finding suggests that ESA has an anti-inflammatory effect in patients with sustained inflammation such as those with heart failure. Since it is well known that IL-6 regulates the hepatic synthesis of CRP, our main finding that CRP was lower in patients using ESA compared to those without ESA agrees with the above evidence.
The most popular class of medication with anti-inflammatory and pleiotropic effects is the statins. Even in patients with end-stage kidney disease, CRP is decreased by 11.5% as a result of statin therapy . However no clinical advantage of statin treatment has been identified in ESKD patients [32, 33]. Because there is little evidence of a beneficial effect of statin therapy for advanced CKD, statins are still not standard treatment for CKD patients, especially those in stages 4 and 5. Therefore, we did not include information on the use of statins in our database.
Because the current study had a cross-sectional design, this is a limitation, since we did not have any information about the duration of each treatment in the predialysis phase, apart from the duration of care by a nephrologist. Based on the hypothesis that there would be a close association between nephrologist care and treatment for the predialysis phase of CKD, all treatments were first adjusted by the duration of care. We consider that this minimized the potential bias. The second limitation of our study is that the marker of chronic inflammation in the predialysis phase of CKD was the serum CRP level measured just before the first dialysis session. We could not completely exclude the possibility that this CRP level did not reflect chronic inflammation in our uremic patients, although we excluded patients with suspected infection (defined as those with an abnormal WBC count). We also excluded patients who are susceptible to latent chronic inflammation, including those with cancer, immune complex disease, or vasculitis, from our final database. However, such exclusions could have narrowed the focus of our investigation.
In conclusion, the present cross-sectional study explored the potential anti-inflammatory effect of common CKD medications in the real world clinical setting. We found that use of ESA had the strongest connection with lower CRP levels. Accordingly, ESA may reduce uremic-specific inflammation in addition to the main effect of these agents on anemia. To confirm these findings, a large-scale longitudinal study will be required.
The authors gratefully acknowledge Hiroyuki Sekihara, Moriaki Osaka, Hiroyuki Miyakawa, Hiromi Okamoto, Kazuhiko Kitano, and Ryoji Kijima for management of the START database.
- Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P: Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative. Eur Hear J. 2010, 31: 703-711. 10.1093/eurheartj/ehp507.View ArticleGoogle Scholar
- K/doqi clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005, 45: S1-153.Google Scholar
- Nakai S, Masakane I, Akiba T, Shigematsu T, Yamagata K, Watanabe Y, Iseki K, Itami N, Shinoda T, Morozumi K, Shoji T, Marubayashi S, Morita O, Kimata N, Shoji T, Suzuki K, Tsuchida K, Nakamoto H, Hamano T, Yamashita A, Wakai K, Wada A, Tsubakihara Y: Overview of regular dialysis treatment in japan as of 31 december 2006. Ther Apher Dial. 2008, 12: 428-456. 10.1111/j.1744-9987.2008.00634.x.View ArticlePubMedGoogle Scholar
- Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P: Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol. 2004, 38: 405-416. 10.1080/00365590410031715.View ArticlePubMedGoogle Scholar
- Joki N, Hase H, Tanaka Y, Takahashi Y, Saijyo T, Ishikawa H, Inishi Y, Imamura Y, Hara H, Tsunoda T, Nakamura M: Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients. Nephrol Dial Transplant. 2006, 21: 1633-1639. 10.1093/ndt/gfl037.View ArticlePubMedGoogle Scholar
- Prasad K: C-reactive protein (crp)-lowering agents. Cardiovasc Drug Rev. 2006, 24: 33-50. 10.1111/j.1527-3466.2006.00033.x.View ArticlePubMedGoogle Scholar
- Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK: Pleiotropic effects of angiotensin ii receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003, 42: 905-910. 10.1016/S0735-1097(03)00846-5.View ArticlePubMedGoogle Scholar
- Mathieu C, Van Etten E, Gysemans C, Decallonne B, Kato S, Laureys J, Depovere J, Valckx D, Verstuyf A, Bouillon R: In vitro and in vivo analysis of the immune system of vitamin d receptor knockout mice. J Bone Miner Res. 2001, 16: 2057-2065. 10.1359/jbmr.2001.16.11.2057.View ArticlePubMedGoogle Scholar
- Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P: Erythropoietin exerts an anti-inflammatory effect on the cns in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002, 952: 128-134. 10.1016/S0006-8993(02)03239-0.View ArticlePubMedGoogle Scholar
- Bazeley J, Bieber B, Li Y, Morgenstern H, de Sequera P, Combe C, Yamamoto H, Gallagher M, Port FK, Robinson BM: C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011, 6: 2452-2461. 10.2215/CJN.00710111.PubMed CentralView ArticlePubMedGoogle Scholar
- Taki K, Niwa T: Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease. J Ren Nutr. 2007, 17: 48-52. 10.1053/j.jrn.2006.10.007.View ArticlePubMedGoogle Scholar
- Shimoishi K, Anraku M, Kitamura K, Tasaki Y, Taguchi K, Hashimoto M, Fukunaga E, Maruyama T, Otagiri M: An oral adsorbent, ast-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res. 2007, 24: 1283-1289. 10.1007/s11095-007-9248-x.View ArticlePubMedGoogle Scholar
- Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A: Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004, 43: 2116-2123. 10.1016/j.jacc.2003.12.051.View ArticlePubMedGoogle Scholar
- Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D: Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The vast study. Clin Ther. 2005, 27: 578-587. 10.1016/j.clinthera.2005.05.006.View ArticlePubMedGoogle Scholar
- Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H: Comparative effects of at1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004, 44: 362-368. 10.1016/j.jacc.2004.03.065.View ArticlePubMedGoogle Scholar
- Fliser D, Buchholz K, Haller H: Antiinflammatory effects of angiotensin ii subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004, 110: 1103-1107. 10.1161/01.CIR.0000140265.21608.8E.View ArticlePubMedGoogle Scholar
- Li C, Sun BK, Lim SW, Song JC, Kang SW, Kim YS, Kang DH, Cha JH, Kim J, Yang CW: Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation. 2005, 79: 1522-1529. 10.1097/01.TP.0000155305.49439.4C.View ArticlePubMedGoogle Scholar
- Koulouris S, Symeonides P, Triantafyllou K, Ioannidis G, Karabinos I, Katostaras T, El-Ali M, Theodoridis T, Vratsista E, Thalassinos N, Kokkinou V, Nanas I, Stamatelopoulos S, Toutouzas P: Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity c-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol. 2005, 95: 1386-1388. 10.1016/j.amjcard.2005.01.092.View ArticlePubMedGoogle Scholar
- Tsikouris JP, Suarez JA, Simoni JS, Ziska M, Meyerrose GE: Exploring the effects of ace inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coronary Artery Dis. 2004, 15: 211-217.Google Scholar
- Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RA, Schalkwijk CG, Ijzerman RG, Twisk JW, Stehouwer CD: Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type ii diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J Hum Hypertens. 2005, 19: 429-437. 10.1038/sj.jhh.1001812.View ArticlePubMedGoogle Scholar
- Hung MJ, Cherng WJ, Cheng CW, Yang NI: Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity c-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease. Am J Cardiol. 2005, 95: 84-87. 10.1016/j.amjcard.2004.08.064.View ArticlePubMedGoogle Scholar
- Ogawa S, Mori T, Nako K, Ito S: Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res. 2008, 31: 1147-1155. 10.1291/hypres.31.1147.View ArticlePubMedGoogle Scholar
- Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised equations for estimated gfr from serum creatinine in japan. Am J Kidney Dis. 2009, 53: 982-992. 10.1053/j.ajkd.2008.12.034.View ArticlePubMedGoogle Scholar
- Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, Kimata N, Shigematsu T, Shinoda T, Syouji T, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Marubayashi S, Morita O, Yamagata K, Wakai K, Watanabe Y, Iseki K, Tsubakihara Y: Overview of regular dialysis treatment in japan (as of 31 december 2008). Ther Apher Dial. 2010, 14: 505-540. 10.1111/j.1744-9987.2010.00893.x.View ArticlePubMedGoogle Scholar
- Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999, 55: 1899-1911. 10.1046/j.1523-1755.1999.00422.x.View ArticlePubMedGoogle Scholar
- Silverstein DM: Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009, 24: 1445-1452. 10.1007/s00467-008-1046-0.View ArticlePubMedGoogle Scholar
- Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with esrd: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005, 16 (Suppl 1): S83-S88.View ArticlePubMedGoogle Scholar
- Hase H, Tsunoda T, Tanaka Y, Takahashi Y, Imamura Y, Ishikawa H, Inishi Y, Joki N: Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int. 2006, 70: 1142-1148. 10.1038/sj.ki.5001726.View ArticlePubMedGoogle Scholar
- Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999, 340: 448-454. 10.1056/NEJM199902113400607.View ArticlePubMedGoogle Scholar
- Dohi Y, Ohashi M, Sugiyama M, Takase H, Sato K, Ueda R: Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res. 2003, 26: 691-697. 10.1291/hypres.26.691.View ArticlePubMedGoogle Scholar
- Kourea K, Parissis JT, Farmakis D, Panou F, Paraskevaidis I, Venetsanou K, Filippatos G, Kremastinos DT: Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble fas/fas ligand system in anemic patients with chronic heart failure. Atherosclerosis. 2008, 199: 215-221. 10.1016/j.atherosclerosis.2007.09.039.View ArticlePubMedGoogle Scholar
- Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009, 360: 1395-1407. 10.1056/NEJMoa0810177.View ArticlePubMedGoogle Scholar
- Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005, 353: 238-248. 10.1056/NEJMoa043545.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.